Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 19/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 10/20 | 0.78 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.78 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.78 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4892177 | 0.99 | PTGS2 (0.76) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL4680 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL29366203 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL30988052 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL29402456 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL14163961 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL5356064 | 0.88 | PTGS2 (0.63) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL4891343 | 0.87 | PTGS2 (0.80) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL321747 | 0.86 | PTGS2 (0.97) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL322344 | 0.86 | PTGS2 (0.97) | PTGS2PTGS1ABCC4ABCB11PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 999 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649049-A2 | PRODUCE TO PRODUCE ETORICOXIB | Virdev Intermediates Pvt. Ltd. (IN) | 2013-10-16 | — | — | EP | claimed |
| US-20130245272-A1 | PROCESS FOR CYCLOOXYGENASE-2 SELECTIVE INHIBITOR | VIRDEV INTERMEDIATES PVT. LTD. (IN) | 2013-09-19 | — | — | US | claimed |
| WO-2012066570-A2 | A PROCESS FOR CYCLOOXYGENASE-2 SELECTIVE INHIBITOR | VIRDEV INTERMEDIATES PVT. LTD. (IN) | 2012-05-24 | — | — | WO | claimed |
| US-7172769-B2 | Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect | PHARMACIA CORPORATION (US) | 2007-02-06 | — | — | US | claimed |
| EP-1239857-B1 | DUAL-RELEASE COMPOSITIONS OF A CYCLOOXYGENASE-2- INHIBITOR | PHARMACIA CORP (US) | 2006-04-19 | — | — | EP | claimed |
| EP-1525883-A1 | Ciclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect | Pharmacia Corporation (US) | 2005-04-27 | — | — | EP | claimed |
| US-20050004199-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | HARTMAN GEORGE (US) | 2005-01-06 | — | — | US | claimed |
| US-20040265382-A1 | Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect | KARARLI TUGRUL T (US) | 2004-12-30 | — | — | US | claimed |
| US-20040242640-A1 | Dual-release compositions of a cyclooxygenase-2 inhibitor | DESAI SUBHASH (IL) | 2004-12-02 | — | — | US | claimed |
| EP-1175214-B1 | CYCLOOXYGENASE-2 INHIBITOR COMPOSITIONS HAVING RAPID ONSET OF THERAPEUTIC EFFECT | PHARMACIA CORP (US) | 2004-11-24 | — | — | EP | claimed |
| US-20020040039-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | HARTMAN GEORGE (US) | 2002-04-04 | — | — | US | claimed |
| WO-2002022124-A1 | TREATMENT OF INFLAMMATION WITH A COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND AN INTEGRIN ALPHA-V ANTAGONIST | MERCK & CO., INC. (US) | 2002-03-21 | — | — | WO | claimed |
| US-20020015735-A1 | Sustained-release formulation of a cyclooxygenase-2 inhibitor | PHARMACIA CORPORATION | 2002-02-07 | — | — | US | claimed |
| EP-1175214-A2 | CYCLOOXYGENASE-2 INHIBITOR COMPOSITIONS HAVING RAPID ONSET OF THERAPEUTIC EFFECT | Pharmacia Corporation (US) | 2002-01-30 | — | — | EP | claimed |
| WO-2001045706-A1 | DUAL-RELEASE COMPOSITIONS OF A CYCLOOXYGENASE-2- INHIBITOR | PHARMACIA CORPORATION (US) | 2001-06-28 | — | — | WO | claimed |
| WO-2001045705-A1 | SUSTAINED-RELEASE FORMULATION OF A CYCLOOXYGENASE-2 INHIBITOR | PHARMACIA CORPORATION (US) | 2001-06-28 | — | — | WO | claimed |
| WO-2001041760-A2 | CYCLOOXYGENASE-2 INHIBITOR COMPOSITIONS HAVING RAPID ONSET OF THERAPEUTIC EFFECT | PHARMACIA CORPORATION (US) | 2001-06-14 | — | — | WO | claimed |
| EP-0912518-A1 | SUBSTITUTED PYRIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1999-05-06 | — | — | EP | claimed |
| US-5861419-A | ANTIINFLAMMATORY AGENTS; ANTIPYRETICS, ANALGESICS; ETORICOXIB PATENT | MERCK FROSST CANAD, INC. (CA) | 1999-01-19 | — | — | US | claimed |
| WO-1998003484-A1 | SUBSTITUTED PYRIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-01-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245272-A1 | PROCESS FOR CYCLOOXYGENASE-2 SELECTIVE INHIBITOR | PTGS2, PTGIS, PTGES2 | PTGS2 1/4885PTGS1 4/4885ABCC4 2658/4885 |
| US-20020040039-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | ITGAV, ITGA5, ITGA2 | PTGS2 28/4885PTGS1 37/4885ABCC4 1871/4885 |
| US-20050004199-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | ITGAV, ITGA5, ITGB5 | PTGS2 27/4885PTGS1 36/4885ABCC4 2019/4885 |
| US-20040242640-A1 | Dual-release compositions of a cyclooxygenase-2 inhibitor | PTGS2, PTGES2, PTGER2 | PTGS2 1/4885PTGS1 4/4885ABCC4 2606/4885 |
| US-20020015735-A1 | Sustained-release formulation of a cyclooxygenase-2 inhibitor | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885ABCC4 1490/4885 |
| US-20040265382-A1 | Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect | PTGES2, PTGS2, PTGS1 | PTGS2 2/4885PTGS1 3/4885ABCC4 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.